Biogen to Pay $900M to Settle Physician Kickback Allegations
Former employee/whistleblower to receive $250 million as part of settlement involving three drugs used to treat muscular sclerosis.
Stay updated with breaking news from Multiple Sclerosis Relapse. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Former employee/whistleblower to receive $250 million as part of settlement involving three drugs used to treat muscular sclerosis.
Ublituximab is superior to teriflunomide in suppressing multiple sclerosis relapses and lesions on MRI, suggest findings from the phase 3 ULTIMATE I and II trials.
The second-generation selective DHODH inhibitor vidofludimus calcium met a phase 2 trial primary endpoint of suppressing new active lesions on MRI and was well tolerated.
The first randomized trial to examine if older adults with multiple sclerosis can discontinue disease-modifying therapy after years of being relapse-free failed to deliver a definitive conclusion.
The novel anti-CD20 monoclonal antibody ublituximab showed greater improvement vs terifulnomide in stabilizing disease progression in relapsing multiple sclerosis in two phase 3 trials.